Concomitant Use of Artificial Tears With RESTASIS®
The therapeutic benefits of using RESTASIS® Ophthalmic Emulsion will occur with continued use by patients over time. Artificial tears, such as OPTIVE™ Lubricant Eye Drops, can be used concomitantly to alleviate dry eye symptoms.
Within a month, patients may start producing more of their own tears. Patients will know they’re getting better when they start feeling less need to use artificial tears. Over the first 6 months of treatment with RESTASIS® Ophthalmic Emulsion, their use of artificial tears is likely to decrease.
Your Patients Can Use OPTIVE™ Lubricant Eye Drops Concomitantly With RESTASIS
OPTIVE™ Lubricant Eye Drops — Dual-action and Long-lasting Relief
OPTIVE™ Lubricant Eye Drops are the only artificial tears designed to work in 2 ways for long-lasting relief of Dry Eye symptoms1,2
The unique formulation of OPTIVE™ provides
- Lubrication — OPTIVE™ acts on the tear film to provide a lubricating and hydrating protective shield to the ocular surface
-and- - Osmoprotection — OPTIVE™ is safely drawn into the corneal epithelial cells below the surface to osmotically protect against hypertonic stress
OPTIVE™ Lubricant Eye Drops contain carboxymethylcellulose for hydration and lubrication, glycerin for deep hydration of the corneal epithelial cells, and PURITE® preservative for gentle, antimicrobial protection.
For more information, please visit www.optivesolutions.com.
References
- Clinical Trial #AG9689-001. Data on file, Allergan, Inc.
- Data on file, Allergan, Inc.
© 2007 Allergan, Inc. All rights reserved | Privacy Statement | FAQs | Terms of Use | Site Map
This information is intended for residents of the United States. ® and ™ marks owned by Allergan, Inc.
RESTASIS® Ophthalmic Emulsion is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs.
Important Safety Information:
RESTASIS® is contraindicated in patients with active ocular infections and has not been studied in patients with a history of herpes keratitis.
The most common adverse event was ocular burning (upon instillation) – 17%. Other events reported in 1% to 5% of patients included conjunctival hyperemia, discharge, epiphora, eye pain, foreign body sensation, pruritus, stinging, and visual disturbance (most often blurring).
Please see full prescribing information for RESTASIS® (cyclosporine ophthalmic emulsion) 0.05%.